



241 Molnar Dr Suite A1 | Elmwood Park, NJ 07407 | (201)791-7293

Director: Seshamma T. Reddy, M.D.
CLIA #: 31D2063148

Client: BIOGENICA
Client #: 1
Chart #: A2304259999
Provider:

Patient: UTI, REP RUN
DOB: 04/25/2023
Gender: M
Specimen Type: URINE
Collected: 04/25/23

Lab Accession #: 2304259999
Accessioned: 04/25/23 10:20
Reviewed & Approved:
Reported:
By:

UTI SUMMARY

ORGANISM(S) DETECTED

Organism	Results	Relative CFU/uL result ^B
Staphylococcus aureus	Detected	MEDIUM
Candida albicans	Detected	MEDIUM

ANTIBIOTIC RESISTANCE GENE(S) DETECTED

Antibiotic Resistance Marker	Presence
mecA Methicillin	PRESENT

^B Relative CFU/uL based on semi-quantitative conversion from real-time PCR of organism genomic DNA.

Approximate ranges of relative CFU/uL include:

LOW: <10² CFU/uL

MED: 10² - 10⁵ CFU/uL

HIGH: >10⁵ CFU/uL

UTI RESULTS

Test	Results	Relative CFU/uL result ^B	Remarks
GRAM NEGATIVE			
Escherichia coli	Not Detected		
Providencia stuartii	Not Detected		
Morganella morganii	Not Detected		
Pseudomonas aeruginosa	Not Detected		
Klebsiella aerogenes	Not Detected		
Proteus vulgaris	Not Detected		
Acinetobacter baumannii	Not Detected		
Enterobacter cloacae	Not Detected		
Citrobacter freundii	Not Detected		
Klebsiella oxytoca	Not Detected		
Klebsiella pneumoniae	Not Detected		
GRAM POSITIVE			
Enterococcus faecalis	Not Detected		
Streptococcus agalactiae	Not Detected		
Staphylococcus aureus	Detected	MEDIUM	
Enterococcus faecium	Not Detected		
FUNGI			
Candida albicans	Detected	MEDIUM	

Test	Presence	Remarks
ANTIBIOTIC RESISTANCE UTI		
VIM Carbapenem	Absent	
SHV ESBL	Absent	
TetM Tetracyclines	Absent	
ampC Beta-lactamase	Absent	
mecA Methicillin	PRESENT	
OXA-1 GES Beta-lactamase	Absent	
KPC Carbapenem	Absent	
Van A/B/C Vancomycin	Absent	
IMP Carbapenem	Absent	
OXA23/24/48/51 Carbapenem	Absent	



Client: BIOGENICA
Client #: 1
Chart #: A2304259999
Provider:

Patient: UTI, REP RUN
DOB: 04/25/2023
Gender: M
Specimen Type: URINE
Collected: 04/25/23

Lab Accession #: 2304259999
Accessioned: 04/25/23 10:20
Reviewed & Approved:
Reported:
By:

Resistance Genes	Antibiotic Resistance Class	Potential Effective		Potential Ineffective	
		Brand Name	Generic Name	Brand Name	Generic Name
VIM	Carbapenem	Principen Amoxil Keflex Zinacef Cephameycins Rocephin Claforan Fortaz Maxipime Azactam Sumycin Vibramycin Minocin Vancocin	Ampicillin Amoxicillin Cephalexin Cefuroxime Cefoxitin Ceftriaxone Cefotaxime Ceftazidime Cefepime Aztreonam Tetracycline Doxycycline Minocycline Vancomycin	Merrem Primaxin Invaz Doribax	Meropenem Imipenem/ cilastatin Ertapenem Doripenem
SHV	ESBL	Sumycin Vibramycin Minocin Vancocin	Tetracycline Doxycycline Minocycline Vancomycin	Principen Amoxil Keflex Zinacef Cephameycins Rocephin Claforan Fortaz Maxipime Merrem Primaxin Invaz Doribax Azactam	Ampicillin Amoxicillin Cephalexin Cefuroxime Cefoxitin Ceftriaxone Cefotaxime Ceftazidime Cefepime Meropenem Imipenem Ertapenem Doripenem Aztreonam
TETM TETS	Tetracycline	Principen Amoxil Keflex Zinacef Cephameycins Rocephin Claforan Fortaz Maxipime Merrem Primaxin Invaz Doribax Azactam Vancocin	Ampicillin Amoxicillin Cephalexin Cefuroxime Cefoxitin Ceftriaxone Cefotaxime Ceftazidime Cefepime Meropenem Imipenem Ertapenem Doripenem Aztreonam Vancomycin	Sumycin Vibramycin Minocin	Tetracycline Doxycycline Minocycline
AmpC	beta-lactamase	Sumycin Vibramycin Minocin Vancocin	Tetracycline Doxycycline Minocycline Vancomycin	Principen Amoxil Keflex Zinacef Cephameycins Rocephin Claforan" Fortaz Maxipime Merrem Primaxin Invaz Doribax Azactam	Ampicillin Amoxicillin Cephalexin Cefuroxime Cefoxitin Ceftriaxone Cefotaxime Ceftazidime Cefepime Meropenem Imipenem Ertapenem Doripenem Aztreonam



Client: BIOGENICA
Client #: 1
Chart #: A2304259999
Provider:

Patient: UTI, REP RUN
DOB: 04/25/2023
Gender: M
Specimen Type: URINE
Collected: 04/25/23

Lab Accession #: 2304259999
Accessioned: 04/25/23 10:20
Reviewed & Approved:
Reported:
By:

Resistance Genes	Antibiotic Resistance Class	Effective		Ineffective	
		Brand Name	Generic Name	Brand Name	Generic Name
mecA	beta-lactamase	Sumycin Vibramycin Minocin" Vancocin	Tetracycline Doxycycline Minocycline Vancomycin	Principen Amoxil Keflex Zinacef Cephamycins Rocephin Claforan" Fortaz Maxipime Merrem Primaxin Invaz Doribax Azactam	Ampicillin Amoxicillin Cephalexin Cefuroxime Cefoxitin Ceftriaxone Cefotaxime Ceftazidime Cefepime Meropenem Imipenem Ertapenem Doripenem Aztreonam
OXA-1 GES	beta-lactamase	Sumycin Vibramycin Minocin" Vancocin	Tetracycline Doxycycline Minocycline Vancomycin	Principen Amoxil Keflex Zinacef Cephamycins Rocephin Claforan" Fortaz Maxipime Merrem Primaxin Invaz Doribax Azactam	Ampicillin Amoxicillin Cephalexin Cefuroxime Cefoxitin Ceftriaxone Cefotaxime Ceftazidime Cefepime Meropenem Imipenem Ertapenem Doripenem Aztreonam
KPC	Carbapenem	Principen Amoxil Keflex Zinacef Cephamycins Rocephin Claforan Fortaz Maxipime Azactam Sumycin Vibramycin Minocin Vancocin	Ampicillin Amoxicillin Cephalexin Cefuroxime Cefoxitin Ceftriaxone Cefotaxime Ceftazidime Cefepime Aztreonam Tetracycline Doxycycline Minocycline Vancomycin	Merrem Primaxin Invaz Doribax	Meropenem Imipenem Ertapenem Doripenem
VAN A B C	Glycopeptide	Principen Amoxil Keflex Zinacef Cephamycins Rocephin Claforan Fortaz Maxipime Azactam Sumycin Vibramycin Minocin	Ampicillin Amoxicillin Cephalexin Cefuroxime Cefoxitin Ceftriaxone Cefotaxime Ceftazidime Cefepime Aztreonam Tetracycline Doxycycline Minocycline	Vancocin	Vancomycin



Client: BIOGENICA
Client #: 1
Chart #: A2304259999
Provider:

Patient: UTI, REP RUN
DOB: 04/25/2023
Gender: M
Specimen Type: URINE
Collected: 04/25/23

Lab Accession #: 2304259999
Accessioned: 04/25/23 10:20
Reviewed & Approved:
Reported:
By:

Resistance Genes	Antibiotic Resistance Class	Effective		Ineffective	
		Brand Name	Generic Name	Brand Name	Generic Name
IMP	Carbapenem	Principen Amoxil Keflex Zinacef Cephameycins Rocephin Claforan Fortaz Maxipime Azactam Sumycin Vibramycin Minocin Vancocin	Ampicillin Amoxicillin Cephalexin Cefuroxime Cefoxitin Ceftriaxone Cefotaxime Ceftazidime Cefepime Aztreonam Tetracycline Doxycycline Minocycline Vancomycin	Merrem Primaxin Invaz Doribax	Meropenem Imipenem Ertapenem Doripenem
OXA-23, 24/40,48,51	Carbapenem	Principen Amoxil Keflex Zinacef Cephameycins Rocephin Claforan Fortaz Maxipime Azactam Sumycin Vibramycin Minocin Vancocin	Ampicillin Amoxicillin Cephalexin Cefuroxime Cefoxitin Ceftriaxone Cefotaxime Ceftazidime Cefepime Aztreonam Tetracycline Doxycycline Minocycline Vancomycin	Merrem Primaxin Invaz Doribax	Meropenem Imipenem Ertapenem Doripenem

* Based on published peer-reviewed antimicrobial guidelines.

These results should be interpreted in the context of other clinical findings to aid in diagnosis and treatment decisions. Test results may be affected by improper specimen collection, improper specimen storage, technical error, contamination, or specimen mix-up. Testing performed by real-time PCR. Tests were developed and performance characteristics determined by Biogenica Laboratory. They have not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes and should not be regarded as investigational or for research. All testing was performed at Biogenica Laboratory.